Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Josh Riggs is CEO and President at Insight Molecular Diagnostics. OQRO lists 3 transactions filed with the SEC under this name, the latest on Mar 30, 2026, each linked to the official Form 4.
CEO and President
Disclosures on record
3
Companies involved
1
Insight Molecular DiagnosticsIMDX
3 disclosures · Mar 2026
Mar 26, 202647Kdisclosed Mar 30
DetailsOfficial recordMar 26, 202647Kdisclosed Mar 30
DetailsOfficial recordMar 26, 202612Kdisclosed Mar 30
DetailsOfficial recordAs of the latest filing on , Josh Riggs reported holding 38,365 shares of Insight Molecular Diagnostics (IMDX), worth about $64K at the last close of $2 (Nov 19, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Insight Molecular Diagnostics IMDX | 38,365 | 38K direct | $2 | $64K | Mar 26, 2026 |
Is this Josh Riggs’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Josh Riggs bought shares on the open market in 2024, and has not bought since 2024.
Josh Riggs reported 1 open-market purchase and 0 sales since 2024; purchases in 2024.
| Year | Bought | Sold |
|---|---|---|
| 2024 | $10K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Mar 26, 2026, Josh Riggs reported holding 38,365 shares of Insight Molecular Diagnostics (IMDX). At the last close of $2 on Nov 19, 2026, that is about $64K. This is the stake disclosed in filings, not a net worth.
No public filing gives Josh Riggs's net worth. What SEC Form 4 shows is the stock stake: 38,365 shares of Insight Molecular Diagnostics (IMDX), about $64K at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
Josh Riggs bought shares on the open market in 2024, and has not bought since 2024.
In SEC filings since 2024: the latest open-market purchase is from 2024; no open-market sale is on record.
Insight Molecular Diagnostics (IMDX), from 2024 to 2024: 1 purchase and 0 sales.
Josh Riggs reported 1 open-market purchase and 0 sales here, 2024.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.